{"id":"W4391303198","doi":"10.1200/jco.2024.42.4_suppl.141","title":"Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; McMaster University; Juravinski Cancer Centre","funders":"ESSA Pharma","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen receptor; Internal medicine; Urology; Regimen; Oncology; Pharmacology; Metastatic breast cancer; Concomitant; Pharmacokinetics; Docetaxel; Tolerability; Chemotherapy; Cancer; Adverse effect; Breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002214099,0.003452942,0.002428027,0.000728132,0.0004946039,0.001322514,0.001229628,0.001988685,0.009488949],"category_scores_gemma":[0.001582497,0.001040069,0.001410957,0.0004803785,0.001236174,0.001634738,0.0004523889,0.004021195,0.001633488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001242845,"about_ca_system_score_gemma":0.002083277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001134552,"about_ca_topic_score_gemma":0.002922027,"domain_scores_codex":[0.9993794,0.0003232651,0.00002042167,0.0001111698,0.00005063255,0.0001151045],"domain_scores_gemma":[0.9990954,0.0001698195,0.000198824,0.00006473772,0.00006165422,0.0004095313],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9075071,0.05025116,0.001224588,0.000398018,0.0004945347,0.00008844461,0.000105541,0.001086563,0.01124397,0.0002311132,0.002950819,0.02441832],"study_design_scores_gemma":[0.721332,0.2719839,0.002534679,0.00001447788,0.00019195,0.00008573972,0.00002770452,0.0009202196,0.001307793,0.0002247145,0.001350936,0.00002587991],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825186,0.001522749,0.0008569486,0.001138792,0.0003886642,0.007490562,0.002701382,0.0002433979,0.003139015],"genre_scores_gemma":[0.9689002,0.001916275,0.003357291,0.00174555,0.0005945271,0.00959583,0.004429245,0.00009216627,0.009368985],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009488949,"threshold_uncertainty_score":0.03174365,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1728041100199732,"score_gpt":0.5116431645062401,"score_spread":0.3388390544862669,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}